[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1112139T1 - Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης - Google Patents

Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης

Info

Publication number
CY1112139T1
CY1112139T1 CY20111101205T CY111101205T CY1112139T1 CY 1112139 T1 CY1112139 T1 CY 1112139T1 CY 20111101205 T CY20111101205 T CY 20111101205T CY 111101205 T CY111101205 T CY 111101205T CY 1112139 T1 CY1112139 T1 CY 1112139T1
Authority
CY
Cyprus
Prior art keywords
ritonavir form
crystall
preparation
pharmaceutical composition
composition including
Prior art date
Application number
CY20111101205T
Other languages
English (en)
Inventor
John F Bauer
Azita Saleki-Gerhardt
Sanjay R Chemburkar
Ketan Patel
Harry O Spiwek
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112139(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1112139T1 publication Critical patent/CY1112139T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Αυτή η Αίτηση Κατοχύρωσης Ευρεσιτεχνίας αφορά την χρήση της κρυσταλλικής ριτοναβίρης Μορφή ΙΙ ως έναν φαρμακευτικό παράγοντα, ως επίσης και μεθόδους παρασκευής φαρμακευτικών συνθέσεων οι οποίες μέθοδοι χρησιμοποιούν την κρυσταλλική ριτοναβίρη Μορφή ΙΙ. Η Αίτηση Κατοχύρωσης Ευρεσιτεχνίας αφορά περαιτέρω μεθόδους για την λήψη της κρυσταλλικής ριτοναβίρης Μορφή Ι, οι οποίες μέθοδοι χρησιμοποιούν την κρυσταλλική ριτοναβίρη Μορφή ΙΙ.
CY20111101205T 1998-07-20 2011-12-05 Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης CY1112139T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04
EP20080007622 EP2017269B1 (en) 1998-07-20 1999-07-19 A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof

Publications (1)

Publication Number Publication Date
CY1112139T1 true CY1112139T1 (el) 2015-11-04

Family

ID=26817251

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100614T CY1111600T1 (el) 1998-07-20 2009-06-11 Αμορφη ριτοναβιρη
CY20111101205T CY1112139T1 (el) 1998-07-20 2011-12-05 Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100614T CY1111600T1 (el) 1998-07-20 2009-06-11 Αμορφη ριτοναβιρη

Country Status (30)

Country Link
EP (4) EP2298751A3 (el)
JP (4) JP4815050B2 (el)
KR (3) KR100853371B1 (el)
CN (5) CN102153524A (el)
AR (5) AR019431A1 (el)
AT (3) ATE261947T1 (el)
AU (1) AU768207B2 (el)
BG (4) BG65150B1 (el)
BR (1) BR9912010A (el)
CA (3) CA2674800A1 (el)
CO (1) CO5090830A1 (el)
CY (2) CY1111600T1 (el)
CZ (2) CZ307116B6 (el)
DE (2) DE69915628T2 (el)
DK (3) DK2017269T3 (el)
ES (3) ES2372990T3 (el)
HK (2) HK1037918A1 (el)
HU (3) HU230150B1 (el)
ID (1) ID27996A (el)
IL (4) IL140492A0 (el)
MY (2) MY121765A (el)
NO (2) NO318385B1 (el)
NZ (2) NZ509125A (el)
PL (2) PL194710B1 (el)
PT (3) PT2017269E (el)
SI (3) SI2017269T1 (el)
SK (3) SK286388B6 (el)
TR (1) TR200100171T2 (el)
TW (3) TWI227713B (el)
WO (1) WO2000004016A2 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
ATE429224T1 (de) * 1999-06-04 2009-05-15 Abbott Lab Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor
MXPA03010771A (es) * 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
WO2013131646A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP0674513B1 (en) * 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
ATE429224T1 (de) * 1999-06-04 2009-05-15 Abbott Lab Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor

Also Published As

Publication number Publication date
HUP0103823A3 (en) 2003-05-28
WO2000004016A3 (en) 2000-03-30
SI1097148T1 (en) 2004-10-31
EP1418174B1 (en) 2009-03-18
ATE261947T1 (de) 2004-04-15
SI1418174T1 (sl) 2009-08-31
NZ509125A (en) 2003-02-28
IL187181A (en) 2009-09-01
JP4815050B2 (ja) 2011-11-16
KR100853371B1 (ko) 2008-08-22
CZ307116B6 (cs) 2018-01-24
CY1111600T1 (el) 2015-10-07
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
CA2674800A1 (en) 2000-01-27
JP2010270135A (ja) 2010-12-02
KR20060118022A (ko) 2006-11-17
JP5732212B2 (ja) 2015-06-10
AR059764A2 (es) 2008-04-30
BG66140B1 (bg) 2011-07-29
WO2000004016A2 (en) 2000-01-27
CA2337846A1 (en) 2000-01-27
EP2017269B1 (en) 2011-11-23
JP2017061475A (ja) 2017-03-30
SK287381B6 (sk) 2010-08-09
IL191582A0 (en) 2008-12-29
CN1310715A (zh) 2001-08-29
CN1502613A (zh) 2004-06-09
ES2214038T3 (es) 2004-09-01
HU0800267D0 (en) 2008-06-30
ES2372990T3 (es) 2012-01-30
CO5090830A1 (es) 2001-10-30
BG110080A (bg) 2008-11-28
CA2510949C (en) 2009-11-17
DE69915628T2 (de) 2004-08-12
EP1418174A3 (en) 2004-06-23
PT1418174E (pt) 2009-06-08
EP2298751A2 (en) 2011-03-23
DK1097148T3 (da) 2004-04-26
EP1418174A2 (en) 2004-05-12
JP2002520410A (ja) 2002-07-09
EP2017269A3 (en) 2009-06-10
CZ298188B6 (cs) 2007-07-18
TWI227713B (en) 2005-02-11
NO20010298D0 (no) 2001-01-18
ATE425974T1 (de) 2009-04-15
AU5003799A (en) 2000-02-07
KR100740796B1 (ko) 2007-07-20
CN102153524A (zh) 2011-08-17
TW200716550A (en) 2007-05-01
SK922001A3 (en) 2001-07-10
NO20010298L (no) 2001-01-18
IL191582A (en) 2016-02-29
BR9912010A (pt) 2001-04-10
EP2017269A2 (en) 2009-01-21
KR20010072003A (ko) 2001-07-31
CN101966180A (zh) 2011-02-09
JP2014074047A (ja) 2014-04-24
BG109682A (bg) 2007-03-30
DE69940616D1 (de) 2009-04-30
EP2298751A3 (en) 2011-08-17
SI2017269T1 (sl) 2012-02-29
ID27996A (id) 2001-05-03
HU0800266D0 (en) 2008-06-30
HK1121155A1 (en) 2009-04-17
NO318385B1 (no) 2005-03-14
AR059763A2 (es) 2008-04-30
TR200100171T2 (tr) 2001-05-21
MY121765A (en) 2006-02-28
EP2017269A8 (en) 2009-09-30
TWI271400B (en) 2007-01-21
DK1418174T3 (da) 2009-05-18
NZ522690A (en) 2004-04-30
PT1097148E (pt) 2004-05-31
CN101259128A (zh) 2008-09-10
KR20040081137A (ko) 2004-09-20
NO20042393L (no) 2001-01-18
AR019431A1 (es) 2002-02-20
PL194710B1 (pl) 2007-06-29
CN1310715B (zh) 2010-11-03
MY145265A (en) 2012-01-13
PL348033A1 (en) 2002-05-06
ATE534636T1 (de) 2011-12-15
CZ2006533A3 (cs) 2001-05-16
HU227540B1 (en) 2011-08-29
HUP0103823A2 (hu) 2002-02-28
AR049658A2 (es) 2006-08-23
EP2017269A9 (en) 2009-10-14
EP1097148A2 (en) 2001-05-09
AU768207B2 (en) 2003-12-04
BG65150B1 (bg) 2007-04-30
KR100793046B1 (ko) 2008-01-10
EP1097148B1 (en) 2004-03-17
HK1037918A1 (en) 2002-02-22
DE69915628D1 (en) 2004-04-22
PT2017269E (pt) 2011-12-20
HU230150B1 (hu) 2015-09-28
AR044029A2 (es) 2005-08-24
BG105197A (en) 2001-10-31
ES2322759T3 (es) 2009-06-26
CA2337846C (en) 2006-02-21
IL140492A0 (en) 2002-02-10
IL140492A (en) 2010-12-30
DK2017269T3 (da) 2012-03-05
SK286388B6 (sk) 2008-09-05
IL187181A0 (en) 2008-02-09
PL213978B1 (pl) 2013-05-31
CA2510949A1 (en) 2000-01-27
BG65963B1 (bg) 2010-07-30
TWI362382B (en) 2012-04-21
CZ2001203A3 (en) 2001-05-16
HU229999B1 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
ES2162614T1 (es) Composiciones formadoras de pelicula que comprenden almidones modificados e iota-carragaenina y metodo para producir capsulas blandas usando las mismas.
AU2001241631A1 (en) Compositions suitable for oral administration and kits and methods thereof for hydrating mammalian skin
ATE246202T1 (de) Gcsf konjugate
HUP0101564A2 (hu) Epotilon készítmények
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
EA200400432A1 (ru) Производные мочевины
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
RU93004445A (ru) Новые 2-циано 3-гидроксиенамидные производные, способ их получения, их применение в качестве медикаментов, содержащие их фармацевтические композиции и новые полученные промежуточные продукты
PL311122A1 (en) Water-solublederivatives of camptotectin, method of obtaining them and their application as anticarcinogenic agents
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
MXPA03004499A (es) Kit de repinotan.
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
EA200300556A1 (ru) Композиция n-(метилэтиламинокарбонил)-4-(3-метилфениламино)-3-пиридилсульфонамида и циклических олигосахаридов
TR200002293T2 (tr) Farmasötik bileşimler.
EA200000530A1 (ru) НОВЫЕ 19-НОРСТЕРОИДЫ, ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 11β, СПОСОБ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης